Eledon Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 13, 2022, covering events that occurred on January 11, 2022. Eledon Pharmaceuticals, Inc. is a Delaware corporation with its principal executive offices in Irvine, California. The company's common stock trades on the Nasdaq Capital Market under the symbol "ELDN."
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a specific capital transaction.
Material Changes
On January 11, 2022, the Company entered into an exchange agreement with specific stockholders (Biotechnology Value Fund entities). Under this agreement:
- 550,000 shares of Common Stock were exchanged for 9,899.99 shares of Series X 1 Preferred Stock.
- The Series X 1 Preferred Stock was issued unregistered, relying on Section 3(a)(9) of the Securities Act.
- Following the exchange, the Company has 13,756,788 shares of Common Stock outstanding.
- There are approximately 117,970 shares of Series X 1 Preferred Stock outstanding, which are convertible into 6,553,894 shares of Common Stock (subject to rounding and beneficial ownership conversion blockers).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies related to the company's operations or financial outlook. The transaction is described as a completed event with the full text of the Exchange Agreement filed as an exhibit.
Investor Verification Checklist
- Verify the terms of the Series X 1 Preferred Stock, including conversion mechanics and beneficial ownership blockers, in the attached Exhibit 10.1.
- Confirm the impact of the 6,553,894 potential conversion shares on total diluted share count.
- Review the identity and relationship of the "BVF Exchanging Stockholders" to understand the strategic context of the exchange.